重组人血管内皮抑制素注射液不同给药途径治疗进展期卵巢癌的效果对比
|
摘要
目的对比重组人血管内皮抑制素注射液不同给药途径在进展期卵巢癌患者中的应用效果。方法选取我院及内蒙古医科大学附属医院收治的进展期卵巢癌患者78例作为研究对象。按照随机数字表法,将其分为两组。对照组39例,以静脉滴注重组人血管内皮抑制素注射液联合紫杉醇与顺铂联合化疗方案(TP)治疗;观察组39例,以持续静脉泵注入重组人血管内皮抑制素注射液联合TP治疗,比较两组患者的治疗效果。结果观察组患者的治疗总有效率略高于对照组,但组间比较,差异无统计学意义(P> 0.05);治疗后,两组患者血清血管内皮生长因子水平均显著改善,且观察组患者的改善程度优于同期对照组,差异具有统计学意义(P <0.05)。结论进展期卵巢癌患者采用持续静脉泵注入重组人血管内皮抑制素注射液联合紫杉醇与顺铂联合化疗方案(TP)治疗治疗效果较好,有利于促使血清血管内皮生长因子水平下降。
Objective To compare the effects of different routes of administration of recombinant human endostatin injection in patients with advanced ovarian cancer. Methods A total of 78 patients with advanced ovarian cancer admitted to our hospital and the Affiliated Hospital of Inner Mongolia Medical University were selected as the research objects.According to the random number table method, they were divided into two groups. In the control group, 39 cases of patients were treated with intravenous drip of human endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP). In the observation group, 39 cases of patients were treated with recombinant human endostatin injection combined with TP by continuous intravenous pump, and the therapeutic effect was compared between the two groups. Results The total effective rate of the observation group was slightly higher than that of the control group, but there was no significant difference between the two groups(P >0.05). After treatment, the levels of serum vascular endothelial growth factor in the two groups were significantly improved, and the improvement degree of the observation group was better than that of the control group at the same time, the difference was statistically significant(P < 0.05). Conclusion Continuous intravenous infusion of recombinant human vascular endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP) is effective in treating advanced ovarian cancer, which is conducive to reducing the level of serum vascular endothelial growth factor.
Objective To compare the effects of different routes of administration of recombinant human endostatin injection in patients with advanced ovarian cancer. Methods A total of 78 patients with advanced ovarian cancer admitted to our hospital and the Affiliated Hospital of Inner Mongolia Medical University were selected as the research objects.According to the random number table method, they were divided into two groups. In the control group, 39 cases of patients were treated with intravenous drip of human endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP). In the observation group, 39 cases of patients were treated with recombinant human endostatin injection combined with TP by continuous intravenous pump, and the therapeutic effect was compared between the two groups. Results The total effective rate of the observation group was slightly higher than that of the control group, but there was no significant difference between the two groups(P >0.05). After treatment, the levels of serum vascular endothelial growth factor in the two groups were significantly improved, and the improvement degree of the observation group was better than that of the control group at the same time, the difference was statistically significant(P < 0.05). Conclusion Continuous intravenous infusion of recombinant human vascular endostatin injection combined with paclitaxel and cisplatin combined chemotherapy(TP) is effective in treating advanced ovarian cancer, which is conducive to reducing the level of serum vascular endothelial growth factor.
引文
[1]张弛,邓文英,李宁,等.恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床观察[J].肿瘤防治研究,2016,43(1):54-57.
[2]梁璐.重组人内皮抑素恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床研究[J].中国医药指南,2017,15(11):35-36.
[3]蔡定贤,唐名杰,王世坤,等.恩度联合GEMOX方案治疗复发或难治性卵巢癌的临床观察[J].中国癌症防治杂志,2015,7(5):360-363.
[4]马纪荣.恩度联合紫杉醇和卡铂方案治疗晚期卵巢癌的临床疗效和安全性研究[J].天津药学,2017,29(1):46-48.
[5]杨阳.恩度联合热灌注化疗对卵巢癌恶性腹水中CECs及VCEC的影响[D].保定:河北大学,2017:12-13.
[6]肖艳.重组人血管内皮抑制素联合化疗治疗卵巢癌合并腹腔积液的疗效观察[J].中国药物与临床,2017,17(7):1062-1065.
[7]崔勇,张荣香,王福立,等. BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果[J].山东大学学报(医学版),2015,53(7):53-57.
[8]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3356.
[9]李春青,牛思强.恩度联合伊立替康治疗复发性卵巢癌疗效分析[J].中国现代药物应用,2014,8(13):11-13.
[10]刘国华.重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效[J].中外医学研究,2014,12(13):3-4.
[11]樊涛,刘修莉,周俊,等.卵巢癌术后恩度腹腔灌注联合静脉化疗的临床观察[J].现代肿瘤医学,2017,25(24):4034-4036.
[12]余建云,曹风军,江良波,等.中晚期卵巢癌恩度联合TP方案化疗的近期疗效观察[J].内蒙古医科大学学报,2018,40(2):160-163.
[2]梁璐.重组人内皮抑素恩度不同给药途径联合TP方案治疗进展期卵巢癌的临床研究[J].中国医药指南,2017,15(11):35-36.
[3]蔡定贤,唐名杰,王世坤,等.恩度联合GEMOX方案治疗复发或难治性卵巢癌的临床观察[J].中国癌症防治杂志,2015,7(5):360-363.
[4]马纪荣.恩度联合紫杉醇和卡铂方案治疗晚期卵巢癌的临床疗效和安全性研究[J].天津药学,2017,29(1):46-48.
[5]杨阳.恩度联合热灌注化疗对卵巢癌恶性腹水中CECs及VCEC的影响[D].保定:河北大学,2017:12-13.
[6]肖艳.重组人血管内皮抑制素联合化疗治疗卵巢癌合并腹腔积液的疗效观察[J].中国药物与临床,2017,17(7):1062-1065.
[7]崔勇,张荣香,王福立,等. BSD2000相控阵聚焦深部热疗联合TP方案化疗治疗晚期卵巢癌的临床效果[J].山东大学学报(医学版),2015,53(7):53-57.
[8]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3356.
[9]李春青,牛思强.恩度联合伊立替康治疗复发性卵巢癌疗效分析[J].中国现代药物应用,2014,8(13):11-13.
[10]刘国华.重组人血管内皮抑制素联合TP方案治疗卵巢癌的近期疗效[J].中外医学研究,2014,12(13):3-4.
[11]樊涛,刘修莉,周俊,等.卵巢癌术后恩度腹腔灌注联合静脉化疗的临床观察[J].现代肿瘤医学,2017,25(24):4034-4036.
[12]余建云,曹风军,江良波,等.中晚期卵巢癌恩度联合TP方案化疗的近期疗效观察[J].内蒙古医科大学学报,2018,40(2):160-163.